Impact of weight loss on survival after chemoradiation for locally advanced head and neck Cancer: secondary results of a randomized phase III trial (SAKK 10/94) | Radiation Oncology | Full Text
Survival Analysis in R
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Let's Flip: An Approach to Understand Median Follow-up by the Reverse Kaplan-Meier Estimator from a Statistical Programmer's
The Treatment Landscape of Metastatic Urothelial Carcinoma: Second-Line Systemic Therapy
Opdualag™ (nivolumab and relatlimab-rmbw) Efficacy in Melanoma
Let's Flip: An Approach to Understand Median Follow-up by the Reverse Kaplan-Meier Estimator from a Statistical Programmer's
Overall survival for suPAR levels above or below a 12 ng/mL cutoff.... | Download Scientific Diagram
Efficacy of KISQALI® (ribociclib) + AI in 1L Postmenopausal | HCP
Society of Urologic Oncology - MANAGEMENT AND OUTCOMES OF PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA OF THE BLADDER: EVOLUTION OF THE UNIVERSITY OF SOUTHERN CALIFORNIA EXPERIENCE OVER 3,347 CASES
Survival Analysis in R
Survival curves. (A) Overall survival (median 18.2 months). (B) PS of... | Download Scientific Diagram
A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time | Scientific Reports
The overall survival did not reach median. The median progression free... | Download Scientific Diagram
survival - Time to event analysis - median (IQR) is <75% experience event - Cross Validated
Survival Analysis
Laying the Foundation Towards Long-Term Survival in Patients with High-Risk Acute Myeloid Leukaemia - European Medical Journal
Overall survival of patients with metastatic breast cancer in Sweden: a nationwide study | British Journal of Cancer
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram
Kaplan-Meier survival analysis
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
